We have studied IL-6 receptor (IL-6R) expression on AML cells from 15 pediatric patients by immunocytochemistry/flow cytometry, reverse-transcription polymerase chain reaction, and Scatchard analysis. High-affinity IL-6R were detected on leukemic cells from 12 (80%) patients. 
Introduction
Acute myelogenous leukemia (AML), accounts for 20% of acute leukemia in children, is the most common leukemia in neonates and infants, and is the most frequent secondary malignancy. 1, 2 Although 60 to 80% of AML patients achieve complete remission on current therapeutic protocols, only 25 to 30% of AML patients will attain long-term disease-free survival, indicating a need for novel therapeutic approaches.
Previous studies have demonstrated the presence of receptors for several cytokines on AML cells. [3] [4] [5] [6] [7] [8] [9] [10] [11] In particular, receptors for IL-6 have been reported on AML cells from adult patients. [5] [6] [7] [8] [9] However, there have been no extensive studies of the incidence and levels of IL-6R expression in pediatric AML. Elevated expression by neoplastic cells of cell-surface molecules such as growth factor receptors and differentiation antigens is of particular interest due to the possibility of using these molecules as targets for recombinant ligand-toxins and immunotoxins. [12] [13] [14] [15] [16] [17] [18] [19] [20] We have previously reported expression of IL-6R on leukemic cells from pediatric AML patients. 21 In the present study, we have detected significant levels of receptor expression on AML blasts from approximately 80% of patients tested. This finding, together with the low level of IL-6R expressed on normal bone marrow cells, prompted us to examine the sensitivity of IL-6R
+ AML cells to a recombinant toxin consisting of IL6 linked to a modified form of Pseudomonas exotoxin (IL6-PE 4E ). 16, 18 In this construct, the toxicity and specificity of the chimeric toxin was enhanced by substitution of four glutamine residues for naturally occurring amino acids in PE domain I. We have initially evaluated the efficacy of IL6-PE 4E for ex vivo purging of IL-6R + AML cells in an autologous bone marrow transplantation setting, using the SCID mouse model to monitor the leukemic engraftment potential of treated cells.
Materials and methods

Patients and cell lines
Bone marrow (BM) cells were obtained from 15 pediatric patients with acute myelogenous leukemia (AML) treated at Emory at either initial diagnosis or relapse. Leukemia was classified by immunophenotypic and the French-AmericanBritish (FAB) criteria; clinical, karyotypic and immunophenotyping data are given in Table 1 . Patients were treated according to Pediatric Oncology Group (POG) protocols. The IL-6R + multiple myeloma cell line U266 served as a postive control for Scatchard analysis and in vitro sensitivity testing. Bone marrow cells from normal pediatric bone marrow transplant donors served as normal controls. Consent for obtaining leukemic and normal cells was obtained from all patients and/or parents, and all protocols were approved by the Human Investigations Committee of Emory University School of Medicine.
Purification of leukemic cells
Leukemic cells were isolated from bone marrow samples by Ficoll-Hypaque centrifugation at 100 g for 15 min. Leukemic cells that were not used immediately were suspended in culture medium containing 10% dimethyl sulfoxide and cryopreserved in liquid nitrogen. Cryopreserved BM samples were thawed, subjected to Ficoll-Hypaque centrifugation to remove nonviable cells, and washed three times in serum-free (SF) RPMI-1640. The post-Ficoll cells were Ͼ80% blasts with at least 80% viability by trypan blue exclusion.
Reverse-transcription polymerase chain reaction (RT-PCR)
Expression of IL-6R mRNA was initially detected by a modified quantitative RT-PCR assay. 8 RNA was extracted using a rapid method (Ultraspec-II RNA isolation reagent; Biotecx Laboratories, Houston, TX, USA). After ethanol precipitation, purified RNA was dried in a vacuum, eluted in 50 l diethylpyrocarbonate (DEPC)-treated water, and stored at −20°C until ready for use. PCR was performed with cDNA derived by reverse transcription of 83 ng of total RNA, using specific upstream and downstream primers for the IL-6R gene and 27 cycles of amplification. 8, 22, 23 These conditions were selected to yield a PCR product on the linear range of the amplification curve and permitted detection of significant levels of IL-6R gene expression in AML specimens with minimal background from normal bone marrow cells (as determined by assays on normal bone marrow specimens). Electrophoresis of the PCR product was performed on 1.3% agarose gels containing ethidium bromide (EB). Bands were visualized by UV transillumination and photographed. Beta-actin gene was used as an internal standard to normalize for RNA loading (data not shown).
Immunocytochemistry (IC) and flow cytometry
The expression of cell-surface IL-6R protein was confirmed by staining cytospin preparations of AML cells using a primary monoclonal anti-IL6-R antibody (MT18; gift of T Kishimoto, Osaka University, Japan) and the alkaline phosphatase antialkaline phosphatase (APAAP) immunocytochemical method (APAAP Kit TM ; Dako, Carpinteria, CA, USA). 24, 25 Negative controls used an irrelevant murine IgM as primary antibody.
IL-6R
+ leukemic cells showed a characteristic bright red precipitate associated with the cell membrane (data not shown).
Expression of IL-6R protein was also evaluated by flow cytometry using biotinylated rhIL-6 (Fluorokine; R&D Systems, Minneapolis, MN, USA). Ficoll-Hypaque-separated bone marrow cells from five IL-6R + AML patients (selected for positivity by IC and RT-PCR) and from a normal pediatric marrow transplant donor were washed in phosphate-buffered saline containing 1% bovine serum albumin and 0.01% (w/v) sodium azide (PBS-BSA). Cells (2 × 10 5 in a 25 l volume) were incubated with biotinylated rhIL-6 (10 l) for 60 min at 4°C. As a negative control, a duplicate sample was stained with biotinylated negative control reagent (irrelevant biotinylated protein; R&D Systems). Avidin-FITC (10 l) was then added to each tube, and the cells were incubated for an additional 30 min at 4°C in the dark. Cells were washed twice and resuspended in PBS-BSA (0.2 ml) for flow cytometric analysis at 488 nm wavelength using a FACScan (Becton Dickinson, Mountain View, CA, USA).
Scatchard analysis of IL6-R expression
The number and binding-affinity of IL-6R on primary AML mononuclear cells was determined by Scatchard analysis of binding assay data using standard methods, 26, 27 Specific binding of (Immunex, Seattle, WA, USA). Cells were incubated for 2.5 h at 4°C with gentle mixing on a platform mixer. The mixture was quickly layered onto 300 l ice-cold (4°C) FCS in a 500 l microcentrifuge tube and centrifuged at 3000 g for 3 min to separate free from bound label. Fifty microliters of the supernatant was removed for gamma counting to determine unbound (free) c.p.m. The remaining supernatant was discarded, the tube cut just above the pellet, air dried for 15 min, and counted in a gamma counter to yield bound c.p.m. , a non-toxic form in which the catalytic domain of PE has been inactivated by substitution of aspartic acid for glutamine 553. 18 The ID 50 values (50% inhibitory dose) for each specimen were calculated by graphical interpolation from the dose-response curves shown in Figure 3 .
Efficacy of IL6-PE 4E for bone marrow purging
To investigate the ability of in vitro treatment with IL6-PE 4E to inhibit leukemic engraftment in SCID mice, bone marrow blasts from patient UPN5 (M5a AML, 2,950 IL-6R/cell) were incubated in vitro with 10 3 ng/ml IL6-PE 4E for 24 h. Following treatment, 43% of these cells appeared to be viable by trypanblue exclusion. A total of 5 × 10 6 trypan blue negative cells/mouse were injected via the tail vein into SCID mice (7-week-old female CB17 scid/scid; Charles River Laboratories, Cambridge, MA, USA); mice were pre-treated with 400 cGy TBI prior to inoculation. 29, 30 Control mice were inoculated with 5 × 10 6 cells incubated with PE40 (a truncated, 40 kDa form of PE lacking the cell-binding domain of the native exotoxin) or with media alone. Control mice were euthanized after developing signs of disease, and histological analysis was performed on tissue and BM. Asymptomatic long-term SCID survivors receiving IL6-PE 4E treated cells were euthanized and examined for occult disease by PCR analysis for a DNA sequence in exon-1 of the human ␤-globin gene. 31, 32 Two 20-mer primers specific for a 110-bp exon-1 fragment were synthesized at the Emory University Microchemical facility based on previously described sequences (PC03 and PC04, Ref. 31) . Sixty cycles of PCR amplification were performed using 1 g genomic DNA (obtained from bone marrow, liver and spleen) and a program of 95°C for 1 min, 55°C for 1 min, and 72°C for 1.5 min; additionally, the 72°C elongation step was extended for 2 s after each cycle and for 10 min after 60 cycles. Amplified DNA was detected by electrophoresis on 3% agarose gels. Negative controls included genomic DNA from an uninoculated SCID mouse as well as PCR reaction buffer without DNA. Positive controls consisted of DNA from inoculated, untreated mice following development of symptoms.
Results
Characterization of IL-6R
+ AML cells
To determine the presence and quantity of IL-6R, bone marrow aspirates were obtained from 10 newly diagnosed patients and five relapsed patients. Patients had immunophenotypic and cytogenetic characteristics typical of AML ( Table 1 ). The majority of patients were CD13 and/or CD33-positive, cytochemically myeloid (positive for myeloperoxidase, Sudan Black B and/or alpha-naphthyl butyrate esterase) and expressed other myeloid associated antigens including CD11b, CD14 and CD15. 33 Several patients also expressed lymphoid-associated antigens including CD7, CD5, CD8, CD19 and TdT. 33 There was no obvious correlation between expression of IL-6R and disease stage (ie diagnosis vs relapse), FAB type or other clinical, immunophenotypic or cytogenetic characteristics.
Expression of IL6-R protein and IL6-R gene in leukemic cells
As an initial screen to detect expression of the IL-6R gene, we performed a semi-quantitative RT-PCR assay (Table 2 ). Of the 13 AML patients analyzed by RT-PCR, 10 (77%) were positive for IL-6R mRNA. Expression of cell-surface IL-6R protein was confirmed by IC in 7/11 (64%) patients and by ligand-binding studies in 12/15 (80%). Four cases with strong expression by RT-PCR and IC (UPN 2, 5, 8 and 14) were also stained with biotinylated rh1L-6 and examined by flow cytometry. All of these cases showed Ͼ80% of cells were positive for IL-6R, consistent with the percentage of blasts in the FicollHypaque-separated specimens used for the analysis; a representative case (UPN 2) is shown in Figure 1 . Bone marrow cells from a normal pediatric donor (UPN16) were Ͻ5% positive by IC and flow cytometry (Figure 1 ), and were faintly positive by PCR. There was a high correlation between mRNA expression by RT-PCR and protein expression by IC and/or ligand-binding. All patients who were positive for IL-6R by RT-PCR and/or IC showed measurable ligand-binding (Table 2) . Conversely, all patients who were negative by RT-PCR and IC assays were also negative for ligand-binding.
Quantitation of cell-surface IL-6R expression by AML
Scatchard analysis of the binding data revealed a single class of high-affinity receptors on leukemic cells from 12/15 (80%) primary AML patients (Figure 2 ). Receptor densities on these patients ranged from 140 to 3580 IL-6R/cell (median, 920; mean 1240) and binding affinities from 0.26 to 0.71 nM (median, 0.45 nM; mean, 0.47 nM). Three of 15 AML patients (UPN1, 9 and 12) had IL-6R expression below the level of detection (Ͻ20 IL6-R/cell). The U266 line expressed 9320 IL-6R/cell with a K d of 0.42 nM, which is similar to that reported previously. 15, 17, 21 Receptor expression by normal BM mononuclear cells from a pediatric bone marrow donor (UPN16) were below the level of detection by Scatchard, analysis, although a faint IL-6R specific band was visible by RT-PCR (data not shown).
Sensitivity of AML cells to IL6-PE
4E
Recombinant IL6-PE 4E produced a dose-dependent reduction in cell viability for all IL-6R + leukemic specimens studied (Figure 3) . The ID 50 values calculated by graphical interpolation from the dose-response curves ranged from 21 to Ͼ10 3 ng/ml for a 48 h drug exposure (Table 2 ). Leukemic cells from eight patients had ID 50 values of Ͻ10 3 ng/ml (median, 87 ng/ml; mean, 262 ng/ml). Five of six specimens with Ͼ10 3 IL-6R/cell had ID 50 values of Ͻ100 ng/ml; the exception (UPN14 with 1080 IL-6R/cell) was relatively resistant, with an ID 50 of 590 ng/ml. A significant negative correlation was noted between IL-6R density and IC 50 , with higher receptor levels being associated with greater sensitivity to recombinant toxin (Spearman correlation coefficient, −0.96, P Ͻ 0.0001) (Figure 4) . 34 All specimens that were negative for IL-6R (UPN1, 9 and 12) by Scatchard analysis were resistant to IL6-PE 4E (ID 50 Ͼ10 3 ng/ml), as were three specimens (UPN 4, 7, 11) with Ͻ500 IL6-R/cell. Similarly, bone marrow mononuclear cells from a normal pediatric bone marrow (UPN16) were resistant to IL6-PE 4E . We were unable to determine the ID 50 for UPN15 due to insufficient numbers of cryopreserved cells. Correlation of IL6-PE 4E ID 50 values with IL-6R densities for 15 primary AML patients. Spearman's correlation coefficient for these two parameters was equal to −0.96; (P Ͻ 0.0001). All UPN with Ͼ10 3 IL-6R/cell had an ID 50 of Ͻ10 2 ng/ml except for UPN14 (1080 IL6-R/cell, ID 50 = 590). The IL-6R density per cell and ID 50 data are shown in Table 3 .
Effect of in vitro IL6-PE
Figure 5
Effect of in vitro treatment with IL6-PE 4E on the ability of primary AML cells from UPN5 (2950 IL6-R/cell) to engraft in SCID mice. UPN5 cells were incubated with 10 3 ng/ml IL6-PE 4E for 24 h and injected i.v. into mice at 10 7 cells/mouse (n = 3-4 mice). Controls consisted of cells incubated with PE40 or media alone. No significant differences in survival were noted between mice receiving untreated or controltreated cells (median survival, 55 days). Mice injected with IL6-PE 4E -treated cells remained asymptomatic at day 185; no occult disease was detected in these mice by PCR analysis for human ␤-globin genomic sequences.
to detect a 110 bp fragment from exon-1 of the human ␤-globin gene by PCR analysis of bone marrow, liver and spleen.
Discussion
To our knowledge this study is the first to: (1) quantitate IL-6R expression by pediatric AML cells and (2) examine the potential utility of IL6-PE 4E for ex vivo purging of primary AML blasts. Previous studies have reported that adult AML cells express IL-6R.
3,5-9 Inoue et al 8 and Sugiyama et al 9 detected IL-6R mRNA expression using semi-quantitative RT-PCR in all AML and acute mixed lineage leukemia (AMLL) patients examined, including six pediatric cases in the former study; however, they did not evaluate expression of IL-6R protein by these cells. Similar findings were reported by Lopez et al 6 who detected expression of the IL-6R gene by leukemic cells from adult AML patients, using Northern blotting to detect gene expression. These investigators also detected expression of cell-surface IL-6R in a fluorescence assay (binding of biotinylated IL-6 as detected by flow-cytometry) in two of three IL-6R + cases studied; however, there was no quantitation of receptor density on these cells. Recently, Rozemuller et al 35 using a similar immunofluorescence assay, have reported that leukemic cells from five of 10 AML patients expressed significant levels of IL-6R.
In the present study, leukemic cells from 12 of 15 (80%) pediatric AML patients expressed cell-surface IL-6R in a ligand-binding assay, and Scatchard analysis showed elevated receptor densities ranging from 140 to 3580 IL-6R/cell (median, 920; mean 1240). We also evaluated IL-6R expression by a semi-quantitative RT-PCR assay for IL-6R mRNA levels, as well as by immunocytochemistry (IC) and a fluorescence assay utilizing biotinylated rhIL-6. These assays were used to screen AML patients for receptor expression and to identify methods that might be clinically useful in selecting patients for therapy with IL6-PE. Due to clinical utility and the high correlation between IC positivity and sensitivity to IL6-PE, IC should be applicable for selecting patients for in vitro sensitivity testing. Alternatively, flow cytometry might be useful for patient selection.
IL-6R expression was detected in each FAB subtype except for M3, which was represented by only one patient. In comparison, IL-6R expression by normal bone marrow mononuclear cells was below the level of detection in the above assay, although expression could be detected by RT-PCR. This finding is consistent with previous studies showing low levels of IL-6R on normal bone marrow cells. 27, 36 Furthermore, we have previously reported that clonogenic growth of normal bone marrow progenitor cells, including granulocytemacrophage colony-forming cells (CFU-GM) and erythroid colony-forming cells (burst-forming unit-erythroid or BFU-E), was not inhibited by IL6-PE 4E at concentrations up to 10 3 ng/ml, suggesting a low level of IL-6R expression on these cells. 32 The biologic significance of IL-6R expression in AML and other acute leukemias including ALL is uncertain. Inoue et al 8 examined the proliferative response of IL-6R + leukemic cells (as determined by an RT-PCR assay for IL-6R mRNA expression) to IL-6 in a DNA-synthesis assay. They found that leukemic cells from two of seven IL-6R + AML showed slight but significant proliferative responses to IL-6 (stimulation indices of 1.3-1.5), while DNA synthesis in one case was inhibited. In our study, all three IL-6R + AML cases tested (UPN 2, 8 and 10) failed to show significant enhancement of DNA synthesis when cultured with rhIL-6 (100 U for 72 h). Moreover, we did not find evidence that IL-6 might serve as a survival factor for IL-6R + AML cells; there was no significant difference in viability of the above IL-6R + cells (by XTT or trypan-blue viability assays) when incubated with or without IL-6 in 48-72 h cultures (data not shown).
The presence of elevated IL-6R levels on AML cells compared to normal bone marrow cells suggests that this receptor might be a target for an IL-6 linked toxin such as IL6-PE 4E , in which the gene for IL-6 has been ligated to a modified Pseudomonas exotoxin gene to create a chimeric protein. We have previously examined the sensitivity of IL-6R + leukemic cells from pediatric acute lymphoblastic leukemia (ALL) patients to recombinant IL6-PE 4E . 36 In the previous study, we detected high levels of IL-6R expression (Ͼ10 3 /cell) on leukemic cells from some cases of t(4;11)+ ALL cells co-expressing multiple myeloid antigens, particularly those positive for the myeloidassociated CD33 antigen; these cells were sensitive to relatively low concentrations of IL6-PE 4E (Ͻ100 ng/ml). Similarly, studies of multiple myeloma have detected elevated IL-6R expression on myeloma cells, which was associated with sensitivity to nanomolar concentrations of IL6-PE 4E . 18 In the present study, we examined the effect of IL6-PE 4E on AML cell viability, using a standard drug-sensitivity assay currently used by the National Cancer Institute to screen new cytotoxic agents for antitumor efficacy. 26, 37 We observed a range of sensitivities to IL6-PE 4E among IL-6R + AML specimens, with ID 50 values of 21 to Ͼ10 3 ng/ml (median, 87 ng/ml; mean, 262 ng/ml) for a 48 h drug exposure. Seven of 15 patients examined expressed Ͼ10 3 IL-6R/cell, and five of these had ID 50 values of Ͻ100 ng/ml (one of these IL-6R + specimens was not available for sensitivity testing). This is in contrast to the relative resistance shown by normal myeloid and erythroid clonogenic progenitor cells, which were not inhibited by up to 10 3 ng/ml IL6-PE
4E
. 32 Significantly, a high negative correlation was noted between IL-6R density and sensitivity to IL6-PE 4E as measured by ID 50 values. Conversely, specimens without detectable IL-6R expression were very resistant to IL6-PE 4E (ID 50 Ͼ10 3 ng/ml), demonstrating the specificity of the recombinant toxin for receptor-positive cells. A specificity control utilizing a non-toxic form of IL6-PE (IL6-PE ASP553 ) did not result in loss of cell viability in cells that were sensitive to IL6-PE 4E , indicating that cytotoxicity was not simply due to blockade of IL-6 receptors on these cells.
Our results are consistent with those of Rozemuller et al, 35 who have studied the in vitro sensitivity of AML cells to IL6-PE 4E using a DNA synthesis assay. These investigators reported that cells from four out of five patients with IL-6R
+ blasts (as detected by flow cytometry) showed inhibition of thymidineincorporation during a 72 h incubation with recombinant toxin. A range of sensitivities was noted for these four specimens, with IC 50 values for DNA synthesis of 70 to 10 3 ng/ml. In this study, we have examined the effect of IL6-PE 4E on cell viability more directly by means of the XTT cytotoxicity assay.
To evaluate the possibility of using IL6-PE 4E as an ex vivo bone marrow purging agent in an autologous transplantation (ABMT) setting, we examined the ability of in vitro incubation with IL6-PE 4E to prevent engraftment of primary AML cells in SCID mice. Leukemic cells from a patient with relapsed, IL-6R + acute monocytic leukemic (M5a phenotype) expressing 2950 receptors/cell were treated with 10 3 ng/ml IL6-PE 4E for 24 h. Cell viability following incubation was 43% by trypanblue exclusion. Inoculation of 5 × 10 6 trypan-blue-negative treated cells into SCID mice failed to produce engraftment, although inoculation of an equal number of untreated or control-treated cells resulted in 100% engraftment. Furthermore, we were unable to detect leukemic cells by PCR analysis for the human ␤-globin gene at up to 6 months after inoculation, indicating lack of residual AML cells in bone marrow, liver and spleen. Thus, a relatively brief exposure to a high concentration of IL6-PE 4E appeared to induce commitment to cell death in these cells. Based on this data and the above cytotoxicity data suggesting the relative resistance of normal marrow progenitor cells compared to IL-6R + AML cells, we speculate that patients expressing Ͼ10
3 IL-6R/blast may be candidates for bone marrow purging; our series of unselected patients suggests that this might include 40-45% of pediatric AML patients, although each patient should be evaluated for sensitivity to IL6-PE 4E by an in vitro cytotoxicity method such as the XTT assay.
Availability on an ex vivo marrow purging protocol for AML would be valuable in cases lacking an HLA-matched donor. Use of immunotoxins with and without pharmacologic agents has been investigated for bone marrow purging in poorprognosis ALL. 31, [38] [39] [40] [41] [42] The relatively high levels of IL-6R on leukemic cells from some AML patients compared to normal bone marrow progenitor cells, together with the apparent efficacy of IL6-PE 4E in preventing engraftment of IL-6R + AML cells in SCID mice, suggests that this agent may be useful for ex vivo purging in AML. Additional studies are in progress to evaluate the sensitivity of engrafted IL-6R
+ AML cells to in vivo therapy with IL6-PE 4E in the SCID model.
